DOCSLIB.ORG

Antibiotic Prescribing for Acute Bronchitis: How Low Can We Go?

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Antibiotic Prescribing for Acute Bronchitis: How Low Can We Go? J Am Board Fam Pract: first published as 10.3122/15572625-13-6-462 on 1 November 2000. Downloaded from Antibiotic Prescribing for Acute Bronchitis: How Low Can We Go? By the time I graduated from medical school in of that wise philosopher Pogo, "We have seen the 1975, I had learned that most respiratory tract enemy, and he is us." infections in otherwise healthy children and adults No doubt, we can do better. Several investiga­ were caused by viruses, such as parainfiuenza, in­ tors have described successful methods of reducing fluenza, adenovirus, and respiratory syncytial virus. antibiotic use for respiratory tract infections. This learning was reinforced during my family Gonzales et al2 found that combined patient and practice residency training in Charleston, Se. I was clinician education was effective in reducing anti­ taught that the challenge of primary care practice is biotic use for acute bronchitis from 74% to 48% in to distinguish the many patients with benign, self­ a health maintenance organization setting. Using a limited respiratory tract infections from those pa­ quality improvement approach and a computer­ tients who are more seriously ill with bacterial based patient record in an academic family practice pneumonia and who need an antibiotic to recover setting, Ornstein and colleagues3 reduced antibi­ more quickly and more certainly. Anned with this otic prescribing for acute bronchitis from 60% to scientific knowledge, I marched valiantly into prac­ less than 30%. tice, determined to base my prescribing on good These and other initiatives show that it is pos­ science. It was only in rural practice that I clearly sible to reduce use of antibiotics for acute respira­ recall regularly confronting syndromes called tory tract infections, but how low can we go? The 4 "acute bronchitis" and "sinusitis," for which pa­ report by Hueston et al in this issue of the JABFP suggests that, for patients with the diagnosis of tients seemed to expect an antibiotic and for which acute bronchitis, the answer might not be 0%. their previous physicians had prescribed one. "I get After the successful campaign to reduce antibiotic this bronchitis every fall. Dr. Smith gives me a shot use for acute bronchitis by Ornstein et aV a stub­ of penicillin and I'm fine 2 days later." With mod­ born residual of 26% of patients received an anti­ est success I was able to talk patients out of this biotic. Why? To answer this question, Hueston approach, but I more frequently failed than suc­ and colleagues compared clinical characteristics of ceeded, though many were willing to take my pre­ patients who received an antibiotic with those who scription for pills as an acceptable alternative to the did not in a retrospective chart review conducted shot in the buttock. http://www.jabfm.org/ after the largely successful intervention. They com­ A quarter-century later I am still fighting the pared clinician characteristics as well. The investi­ good battle of appropriate antibiotic use for respi­ gators nearly came up empty handed. Patients' ratory tract infections. After a 25-year cold war, signs and symptoms were poor predictors of anti­ however, the battle is heating up! The Centers for biotic prescribing in these recalcitrant cases. There Disease Control and Prevention has entered the were no clinician factors that predicted antibiotic fray, urging us and our patients to use antibiotics prescribing-no "resistant" physicians were found. on 27 September 2021 by guest. Protected copyright. sparingly and wisely for acute respiratory tract in­ The study was, however, underpowered to detect fections. 1 Family physicians have been named as a some potentially important clinical predictors. For major contributor to the problem of bacterial re­ example, an antibiotic was prescribed for 36% of sistance, and the reasons we participate in the prob­ patients with fever, 42% of patients with shortness lem have been thoroughly described. In the words of breath, 56% of patients with chest pain, and 75% of patients with sweats, though a small proportion of patients had these complaints. Presence of pu­ Submitted, 14 August 2000. rulent sputum, a common reason for antibiotic pre­ From the Department of Family Medicine, Michigan State University College of Human Medicine, East Lansing. scribing, was not assessed. Address reprint requests to John M. Hickner, MD, MS, Children were much less likely to receive an Department of Family Practice, Michigan State University College of Human Medicine, B III Clinical Center, Mich­ antibiotic than adults, 3% compared with 34%. igan State University, East Lansing, MI 48824. Patient expectation could not be measured in this 462 JABFP November-December 2000 Vol. 13 No. 6 J Am Board Fam Pract: first published as 10.3122/15572625-13-6-462 on 1 November 2000. Downloaded from study, but it is a likely explanation for this striking was prescribed: Other than the diagnosis, what difference. Perhaps parents are more willing to take other factors did you consider when prescribing an a watch-and-wait approach for their children be­ antibiotic for this patient? Clinicians reported cause the current national antiantibiotic campaign other factors in 95% of cases. The most common has begun to have some effect, whereas adults who reasons were patient not improving (21 %), patient might have received an antibiotic for a similar in­ getting worse (19%), and patient has been sick for fection in the past are more likely to demand an too long (19%). Clinicians prescribed an antibiotic antibiotic. Recently, Dosh and colleaguess found in 98% of cases in which they believed the likeli­ that patient demand for an antibiotic for an upper hood of an adverse outcome was high if no antibi­ respiratory tract infection, acute bronchitis, and otic was prescribed. acute sinusitis was strongly predicted by having How low can we go with antibiotic prescribing received an antibiotic for a previous similar illness. for acute respiratory infections? Here are my tar­ I doubt that patient expectation is the only factor gets for the year 2005: upper respiratory tract in­ driving continued antibiotic prescribing for acute fections 10%; acute bronchitis 25%; acute sinusitis bronchitis as well as other common acute respira­ 50%. Until the prognostic uncertainty of pro­ tory tract infections, or ARIs. (I prefer this termi­ longed symptoms is resolved (or not!) by a large nology rather than the anatomic nomenclature of randomized clinical trial, many physicians will con­ bronchitis, sinusitis, and upper respiratory tract in­ tinue to reach for the prescription pad for patients fection, because the same organism might cause who have acute respiratory tract infections who acute bronchitis in one person, simple upper respi­ have been sick for too long or who are not getting ratory tract infection in another, and acute sinusitis better. in yet another.) Based on my many discussions with John M. Hickner, MD, MS family physicians and from our own research, phy­ East Lansing, Mich sicians do believe that some patients with ARls benefit from antibiotic treatment. In a prospective References descriptive study of diagnosis and treatment of 1. Schwartz B, Bell DM, Hughes JM. Preventing the ARIs in a rural primary care research network, we emergence of antimicrobial resistance: a call for ac­ tion by clinicians, public health officials, and pa­ found a typical pattern of antibiotic prescribing: tients. JAMA 1997;278:944-5. 21 % for upper respiratory tract infections, 80% for 2. Gonzales R, Steiner JF, Lum A, Barrett PH Jr. De­ acute bronchitis, and 98% for acute sinusitis.s In creasing antibiotic use in ambulatory practice: im­ this "untrained" group of physicians and patients, pact of a multidimensional intervention on the treat­ antibiotic prescribing was not independently pre­ ment of uncomplicated acute bronchitis in adults .. http://www.jabfm.org/ dicted by any symptoms but was predicted by a JAMA 1999;281:1512-9. small number of physical findings: discolored nasal 3. Ornstein SM, Jenkins RG, Lee FW, et. al. The computer-based patient record as a CQI tool in a discharge, rales or rhonchi, sinus tenderness, and family medicine center. Jt Comm J Qual Improv postnasal drainage. Surprisingly, patient expecta­ 1997;23:347-61. tion was not an independent predictor of antibiotic 4. Hueston W}, Hopper JE, Dacus EN, Mainous AG, prescribing. Roetzhein RG. Why are antibiotics prescribed for Hueston and colleagues speculate that factors patients with acute bronchitis? A postintervention on 27 September 2021 by guest. Protected copyright. other than signs, symptoms, and clinician charac­ analysis. J Am Board Fam Pract 2000;13:398-402. teristics predict antibiotic prescribing for acute 5. Dosh S, Hickner JM, Mainous AG 3rd, Ebell M. Predictors of antibiotic prescribing for nonspecific bronchitis. I agree. In our study of ARIs, we ex­ upper respiratory infections, acute bronchitis, and plored this issue by asking clinicians the following acute sinusitis: an UPRNet study. Upper Peninsula question for each patient for whom an antibiotic Research Network. J Fam Pract 2000;49:407-14. Editorials 463 .
Load more

Recommended publications
  • Allergic Bronchopulmonary Aspergillosis Revealing Asthma
    CASE REPORT published: 22 June 2021 doi: 10.3389/fimmu.2021.695954 Case Report: Allergic Bronchopulmonary Aspergillosis Revealing Asthma Houda Snen 1,2*, Aicha Kallel 2,3*, Hana Blibech 1,2, Sana Jemel 2,3, Nozha Ben Salah 1,2, Sonia Marouen 3, Nadia Mehiri 1,2, Slah Belhaj 3, Bechir Louzir 1,2 and Kalthoum Kallel 2,3 1 Pulmonary Department, Hospital Mongi Slim, La Marsa, Tunisia, 2 Faculty of Medicine, Tunis El Manar University, Tunis, Tunisia, 3 Parasitology and Mycology Department, La Rabta Hospital, Tunis, Tunisia Allergic bronchopulmonary aspergillosis (ABPA) is an immunological pulmonary disorder caused by hypersensitivity to Aspergillus which colonizes the airways of patients with asthma and cystic fibrosis. Its diagnosis could be difficult in some cases due to atypical Edited by: presentations especially when there is no medical history of asthma. Treatment of ABPA is Brian Stephen Eley, frequently associated to side effects but cumulated drug toxicity due to different molecules University of Cape Town, South Africa is rarely reported. An accurate choice among the different available molecules and Reviewed by: effective on ABPA is crucial. We report a case of ABPA in a woman without a known Shivank Singh, Southern Medical University, China history of asthma. She presented an acute bronchitis with wheezing dyspnea leading to an Richard B. Moss, acute respiratory failure. She was hospitalized in the intensive care unit. The Stanford University, United States bronchoscopy revealed a complete obstruction of the left primary bronchus by a sticky *Correspondence: Houda Snen greenish material. The culture of this material isolated Aspergillus fumigatus and that of [email protected] bronchial aspiration fluid isolated Pseudomonas aeruginosa.
    [Show full text]
  • Symptoms Related to Asthma and Chronic Bronchitis in Three Areas of Sweden
    Eur Respir J, 1994, 7, 2146–2153 Copyright ERS Journals Ltd 1994 DOI: 10.1183/09031936.94.07122146 European Respiratory Journal Printed in UK - all rights reserved ISSN 0903 - 1936 Symptoms related to asthma and chronic bronchitis in three areas of Sweden E. Björnsson*, P. Plaschke**, E. Norrman+, C. Janson*, B. Lundbäck+, A. Rosenhall+, N. Lindholm**, L. Rosenhall+, E. Berglund++, G. Boman* Symptoms related to asthma and chronic bronchitis in three areas of Sweden. E. Björnsson, *Dept of Lung Medicine and Asthma P. Plaschke, E. Norrman, C. Janson, B. Lundbäck, A. Rosenhall, N. Lindholm, L. Research Center, Akademiska sjukhu- Rosenhall, E. Berglund, G. Boman. ERS Journals Ltd 1994. set, Uppsala University, Uppsala, Sweden. ABSTRACT: Does the prevalence of respiratory symptoms differ between regions? **Asthma and Allergy Research Center, Sahlgren's Hospital, University of Göteborg, As a part of the European Community Respiratory Health Survey, we present data Göteborg, Sweden. +Dept of Pulmonary from an international questionnaire on asthma symptoms occurring during a 12 Medicine and Allergology, Univer- month period, smoking and symptoms of chronic bronchitis. The questionnaire was sity Hospital of Northern Sweden, Umeå, mailed to 10,800 persons aged 20–44 yrs living in three regions of Sweden (Västerbotten, Sweden. ++Dept of Pulmonary Medicine, Uppsala and Göteborg) with different environmental characteristics. The total Sahlgrenska University Hospital, Göteborg, response rate was 86%. Sweden. Wheezing was reported by 20.5%, and the combination of wheezing without a Correspondence: E. Björnsson, Dept of cold and wheezing with breathlessness by 7.4%. The use of asthma medication was Lung Medicine, Akademiska sjukhuset, S- reported by 5.3%.
    [Show full text]
  • Rhinitis and Sinusitis
    Glendale Animal Hospital 623-934-7243 www.familyvet.com Rhinitis and Sinusitis (Inflammation of the Nose and Sinuses) Basics OVERVIEW Rhinitis—inflammation of the lining of the nose Sinusitis—inflammation of the sinuses The nasal cavity communicates directly with the sinuses; thus inflammation of the nose (rhinitis) and inflammation of the sinuses (sinusitis) often occur together (known as “rhinosinusitis”) “Upper respiratory tract” (also known as the “upper airways”) includes the nose, nasal passages, throat (pharynx), and windpipe (trachea) “Lower respiratory tract” (also known as the “lower airways”) includes the bronchi, bronchioles, and alveoli (the terminal portion of the airways, in which oxygen and carbon dioxide are exchanged) SIGNALMENT/DESCRIPTION OF PET Species Dogs Cats Breed Predilections Short-nosed, flat-faced (known as “brachycephalic”) cats are more prone to long-term (chronic) inflammation of the nose (rhinitis), and possibly fungal rhinitis Dogs with a long head and nose (known as “dolichocephalic dogs,” such as the collie and Afghan hound) are more prone to Aspergillus (a type of fungus) infection and nasal tumors Mean Age and Range Cats—sudden (acute) viral inflammation of the nose and sinuses (rhinosinusitis) and red masses in the nasal cavity and throat (known as “nasopharyngeal polyps”) are more common in young kittens (6–12 weeks of age) Congenital (present at birth) diseases (such as cleft palate) are more common in young pets Tumors/cancer and dental disease—are more common in older pets Foreign
    [Show full text]
  • Rhinotillexomania in a Cystic Fibrosis Patient Resulting in Septal Perforation Mark Gelpi1*, Emily N Ahadizadeh1,2, Brian D’Anzaa1 and Kenneth Rodriguez1
    ISSN: 2572-4193 Gelpi et al. J Otolaryngol Rhinol 2018, 4:036 DOI: 10.23937/2572-4193.1510036 Volume 4 | Issue 1 Journal of Open Access Otolaryngology and Rhinology CASE REPORT Rhinotillexomania in a Cystic Fibrosis Patient Resulting in Septal Perforation Mark Gelpi1*, Emily N Ahadizadeh1,2, Brian D’Anzaa1 and Kenneth Rodriguez1 1 Check for University Hospitals Cleveland Medical Center, USA updates 2Case Western Reserve University School of Medicine, USA *Corresponding author: Mark Gelpi, MD, University Hospitals Cleveland Medical Center, 11100 Euclid Avenue, Cleveland, OH 44106, USA, Tel: (216)-844-8433, Fax: (216)-201-4479, E-mail: [email protected] paranasal sinuses [1,4]. Nasal symptoms in CF patients Abstract occur early, manifesting between 5-14 years of age, and Cystic fibrosis (CF) is a multisystem disease that can have represent a life-long problem in this population [5]. Pa- significant sinonasal manifestations. Viscous secretions are one of several factors in CF that result in chronic sinona- tients with CF can develop thick nasal secretions con- sal pathology, such as sinusitis, polyposis, congestion, and tributing to chronic rhinosinusitis (CRS), nasal conges- obstructive crusting. Persistent discomfort and nasal man- tion, nasal polyposis, headaches, and hyposmia [6-8]. ifestations of this disease significantly affect quality of life. Sinonasal symptoms of CF are managed medically with Digital manipulation and removal of crusting by the patient in an attempt to alleviate the discomfort can have unfore- topical agents and antibiotics, however surgery can be seen damaging consequences. We present one such case warranted due to the chronic and refractory nature of and investigate other cases of septal damage secondary to the symptoms, with 20-25% of CF patients undergoing digital trauma, as well as discuss the importance of sinona- sinus surgery in their lifetime [8].
    [Show full text]
  • Acute (Serious) Bronchitis
    Acute (serious) Bronchitis This is an infection of the air tubes that go down to your lungs. It often follows a cold or the flu. Most people do not need treatment for this. The infection normally goes away in 7-10 days. We make every effort to make sure the information is correct (right). However, we cannot be responsible for any actions as a result of using this information. Getting Acute Bronchitis How the lungs work Your lungs are like two large sponges filled with tubes. As you breathe in, you suck oxygen through your nose and mouth into a tube in your neck. Bacteria and viruses in the air can travel into your lungs. Normally, this does not cause a problem as your body kills the bacteria, or viruses. However, sometimes infection can get through. If you smoke or if you have had another illness, infections are more likely to get through. Acute Bronchitis Acute bronchitis is when the large airways (breathing tubes) to the lungs get inflamed (swollen and sore). The infection makes the airways swell and you get a build up of phlegm (thick mucus). Coughing is a way of getting the phlegm out of your airways. The cough can sometimes last for up to 3 weeks. Acute Bronchitis usually goes away on its own and does not need treatment. We make every effort to make sure the information is correct (right). However, we cannot be responsible for any actions as a result of using this information. Symptoms (feelings that show you may have the illness) Symptoms of Acute Bronchitis include: • A chesty cough • Coughing up mucus, which is usually yellow, or green • Breathlessness when doing more energetic activities • Wheeziness • Dry mouth • High temperature • Headache • Loss of appetite The cough usually lasts between 7-10 days.
    [Show full text]
  • Octreotide Treatment of Idiopathic Pulmonary Fibrosis: a Proof-Of-Concept Study
    drugs, while two patients underwent surgery in addition to Roncaccio 16, 21049, Tradate, Italy. E-mail: giovannibattista. chemotherapy. [email protected] As in other reference centres, the E. Morelli Hospital needs to transfer out all admitted cases to the hospitals referring them for Support Statement: This study was supported by the current specialised treatment, when culture conversion and clinical research funds of the participating institutions. For this stability have been achieved. Patients were transferred out after publication, the research leading to these results has received a median (IQR) hospital stay of 75.5 (51.5–127.5) days; 12 (100%) funding from the European Community’s Seventh Framework out of 12 and nine (75%) out of 12 achieved sputum-smear and Programme (FP7/2007-2013) under grant agreement FP7- culture conversion, after a median (IQR) time of 40.5 (24–64) and 223681. 70 (44–95) days, respectively. As of June 2011, one patient was cured, two had died and nine were still under treatment. Statement of Interest: None declared. Four (33.3%) cases reported adverse events, two being major (16.7%; neuropathy and low platelet count, needing temporary REFERENCES interruption of linezolid) and two minor (neuropathy and mild 1 Villar M, Sotgiu G, D’Ambrosio L, et al. Linezolid safety, anaemia). All adverse events were reversible. tolerability and efficacy to treat multidrug- and extensively drug-resistant tuberculosis. Eur Respir J 2011; 38: 730–733. In conclusion, despite the intrinsic difficulty of evaluating the 2 World Health Organization. Multidrug and extensively drug safety and tolerability of linezolid (administered within different resistant TB (M/XDR-TB): 2010 global report on surveillance and regimens including multiple anti-TB drugs guided by drug response.
    [Show full text]
  • SINUSITIS AS a CAUSE of TONSILLITIS. by BEDFORD RUSSELL, F.R.C.S., Surgeon-In-Charge, Throat Departmentt, St
    Postgrad Med J: first published as 10.1136/pgmj.9.89.80 on 1 March 1933. Downloaded from 80 POST-GRADUATE MEDICAL JOURNAL March, 1933 Plastic Surgery: A short course of lecture-demonstrations is being arranged, to be given at the Hammersmith Hospitar, by Sir Harold Gillies, Mr. MacIndoe and Mr. Kilner. Details will be circulated shortly. Technique of Operations: A series of demonstrations is being arranged. Details will be circulated shortly. Demonstrations in (Advanced) Medicine and Surgeryi A series of weekly demonstrations is being arranged. Details will be circulated shortly. A Guide Book, giving details of how to reach the various London Hospitals by tube, tram, or bus, can be obtained from the Fellowship. Price 6d. (Members and Associates, 3d.). SINUSITIS AS A CAUSE OF TONSILLITIS. BY BEDFORD RUSSELL, F.R.C.S., Surgeon-in-Charge, Throat Departmentt, St. Bart's Hospital. ALTHOUGH the existence of sinus-infection has long since been recognized, medical men whose work lies chiefly in the treatment of disease in the nose, throat and ear are frequently struck with the number of cases of sinusitis which have escaped recognition,copyright. even in the presence of symptoms and signs which should have given rise at least to suspicion of such disease. The explanation of the failure to recognize any but the most mlianifest cases of sinusitis lies, 1 think, in the extreme youth of this branch of medicine; for although operations upon the nose were undoubtedly performed thousands of years ago, it was not uintil the adoption of cocaine about forty years ago that it was even to examine the nasal cavities really critically.
    [Show full text]
  • Allergic Bronchopulmonary Aspergillosis and Severe Asthma with Fungal Sensitisation
    Allergic Bronchopulmonary Aspergillosis and Severe Asthma with Fungal Sensitisation Dr Rohit Bazaz National Aspergillosis Centre, UK Manchester University NHS Foundation Trust/University of Manchester ~ ABPA -a41'1 Severe asthma wl'th funga I Siens itisat i on Subacute IA Chronic pulmonary aspergillosjs Simp 1Ie a:spe rgmoma As r§i · bronchitis I ram une dysfu net Ion Lun· damage Immu11e hypce ractivitv Figure 1 In t@rarctfo n of Aspergillus Vliith host. ABP A, aHerg tc broncho pu~ mo na my as µe rgi ~fos lis; IA, i nvas we as ?@rgiH os 5. MANCHl·.'>I ER J:-\2 I Kosmidis, Denning . Thorax 2015;70:270–277. doi:10.1136/thoraxjnl-2014-206291 Allergic Fungal Airway Disease Phenotypes I[ Asthma AAFS SAFS ABPA-S AAFS-asthma associated with fu ngaIsensitization SAFS-severe asthma with funga l sensitization ABPA-S-seropositive a llergic bronchopulmonary aspergi ll osis AB PA-CB-all ergic bronchopulmonary aspergi ll osis with central bronchiectasis Agarwal R, CurrAlfergy Asthma Rep 2011;11:403 Woolnough K et a l, Curr Opin Pulm Med 2015;21:39 9 Stanford Lucile Packard ~ Children's. Health Children's. Hospital CJ Scanford l MEDICINE Stanford MANCHl·.'>I ER J:-\2 I Aspergi 11 us Sensitisation • Skin testing/specific lgE • Surface hydroph,obins - RodA • 30% of patients with asthma • 13% p.atients with COPD • 65% patients with CF MANCHl·.'>I ER J:-\2 I Alternar1a• ABPA •· .ABPA is an exagg·erated response ofthe imm1une system1 to AspergUlus • Com1pUcatio n of asthm1a and cystic f ibrosis (rarell·y TH2 driven COPD o r no identif ied p1 rior resp1 iratory d isease) • ABPA as a comp1 Ucation of asth ma affects around 2.5% of adullts.
    [Show full text]
  • Obliterative Bronchiolitis, Cryptogenic Organising Pneumonitis and Bronchiolitis Obliterans Organizing Pneumonia: Three Names for Two Different Conditions
    Eur Reaplr J EDITORIAL 1991, 4, 774-775 Obliterative bronchiolitis, cryptogenic organising pneumonitis and bronchiolitis obliterans organizing pneumonia: three names for two different conditions R.M. du Bois, O.M. Geddes Over the last five years, increasing confusion has has been applied to conditions in which airflow obstruc­ developed over the use of the terms "bronchiolitis tion is prominent and in which response to treatment is obliterans" and "bronchiolitis obliterans organizing poor. pneumonia". The confusion stems largely from the common use of the term "bronchiolitis obliterans" or "obliterative bronchiolitis" in the diagnostic labels applied "Cryptogenic organizing pneumonitis" or "bronchi· to two entities which are quite distinct clinically but which otitis obliterans organizing pneumonia" (BOOP) bear certain resemblances histologically. Cryptogenic organizing pneumonitis was first described by DAVISON et al. [7] in 1983. The clinical syndrome ObUterative bronchiolitis consisted of breathlessness, malaise, fever, high erythrocyte sedimentation rate (ESR), pneumonic In 1977, GEODES et al. [1] reported the case histories shadowing on chest radiograph with a restrictive of six patients whose clinical condition was characterized pulmonary function defect and low gas transfer coeffi­ by airways obliteration in association with rheumatoid cient. On histological examination of lung biopsy mate· arthritis. The striking clinical features were of rapidly rial, the typical and distinguishing feature was the progressive breathlessness and the fmding on examination presence of connective tissue within the alveoli, alveolar of a high-pitched mid-inspiratory squeak heard over the ducts and, occasionally, in respiratory bronchioles. This lung fields. Chest radiographs showed hyperinflated lungs connective tissue consisted of "loosely woven fibres of but were otherwise normal.
    [Show full text]
  • Allergic Bronchopulmonary Aspergillosis: a Perplexing Clinical Entity Ashok Shah,1* Chandramani Panjabi2
    Review Allergy Asthma Immunol Res. 2016 July;8(4):282-297. http://dx.doi.org/10.4168/aair.2016.8.4.282 pISSN 2092-7355 • eISSN 2092-7363 Allergic Bronchopulmonary Aspergillosis: A Perplexing Clinical Entity Ashok Shah,1* Chandramani Panjabi2 1Department of Pulmonary Medicine, Vallabhbhai Patel Chest Institute, University of Delhi, Delhi, India 2Department of Respiratory Medicine, Mata Chanan Devi Hospital, New Delhi, India This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. In susceptible individuals, inhalation of Aspergillus spores can affect the respiratory tract in many ways. These spores get trapped in the viscid spu- tum of asthmatic subjects which triggers a cascade of inflammatory reactions that can result in Aspergillus-induced asthma, allergic bronchopulmo- nary aspergillosis (ABPA), and allergic Aspergillus sinusitis (AAS). An immunologically mediated disease, ABPA, occurs predominantly in patients with asthma and cystic fibrosis (CF). A set of criteria, which is still evolving, is required for diagnosis. Imaging plays a compelling role in the diagno- sis and monitoring of the disease. Demonstration of central bronchiectasis with normal tapering bronchi is still considered pathognomonic in pa- tients without CF. Elevated serum IgE levels and Aspergillus-specific IgE and/or IgG are also vital for the diagnosis. Mucoid impaction occurring in the paranasal sinuses results in AAS, which also requires a set of diagnostic criteria. Demonstration of fungal elements in sinus material is the hall- mark of AAS.
    [Show full text]
  • Interstitial Lung Disease
    Interstitial Lung Disease Nitin Bhatt, MD Assistant Professor of Internal Medicine Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine Ohio State University Medical Center Interstitial Lung Disease Jim Allen, MD Professor of Internal Medicine Division of Pulmonary & Critical Care Medicine Ohio State University Medical Center 1 Case #1 Case #1 • 57 y.o. WM with a history of shortness of breath and cough that has been present for 1 year • Initially worse with walking, moderate exertion. No resting symptoms. • Now activity limiting • Associated with a dry, nonproductive cough • Negative cardiac evaluation • PMHx: HTN • Meds: HCTZ • SOCHx: 30 pack year smoking history, quit 10 years ago 2 Case #1 • PE: HR 78, BP 138/67, sats 96% on room air • Lungs with bibasilar dry crackles • Ext with clubbing • PFTs: • FVC 69% predicted • FEV1 72% • TLC 62% • DLCO 53% • 6 Minute walk: Walks 1100 feet with an initial sat of 96% dropping to 79% on room air Case #1 • CT scan • Subpleural fibrosis 3 Case #1 • CT scan • TtibTraction bronchi hitiectasis • • Honeycombing Case #1 • Lunggpy biopsy • Interstitial thickening • Temporal heterogeneity • Fibroblastic foci 4 Idiopathic Pulmonary Fibrosis • Most common ILD of unknown etiology • MilMainly aff fftects peopl e > >50 50 yo, mos t are over the age of 60 yo • Incidence is estimated at 7.4-10.7 cases per 100,000 per year • Prevalence of IPF is estimated at 13-20/100,000 • Most are current or former smokers • Potential risk factors for developing IPF include cigarette smoking, occupational/environmental
    [Show full text]
  • Frequently Asked Questions About Sinusitis Table of Contents
    FREQUENTLY ASKED QUESTIONS ABOUT SINUSITIS TABLE OF CONTENTS Chapter 1: Do I have acute sinusitis or chronic sinusitis? 3 Chapter 2: Do I need antibiotics for my acute sinusitis? 4 Chapter 3: What kind of chronic sinusitis do I have? 5 Chapter 4: Why do I have chronic sinusitis? 7 Chapter 5: What are my treatment options for chronic sinusitis? 9 Chapter 6: When should I consider surgery? 11 Chapter 7: Are my allergies causing my chronic sinusitis? 12 Chapter 8: Is there a connection between chronic sinusitis and asthma? 13 Chapter 9: What can I do to keep my chronic sinusitis under control? 14 Chapter 10: About Metropolitan ENT & Facial Plastic Surgery 15 DISCLAIMER: This information is for educational and informational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this e-book. While all attempts have been made to verify information provided in this publication, the Publisher assumes no responsibility for errors, omissions, or contrary interpretation of the subject matter herein. The content of this e-book was developed and published by eos Healthcare Partners, LLC. Accordingly the information and material in this book is copyright, 2015 © eos Healthcare Partners, LLC.Therefore no part of this book may in any form be reproduced, stored, broadcast, sold or transmitted without the prior permission of the publisher, eos Healthcare Partners, LLC.
    [Show full text]